Kathleen T. Karloff is CEO & Chairman at INVO Bioscience, Inc. (IVOB). They have made 1 open-market trade across 1 company since 2017, most recently 2018-10-31.
CIK 0001493763
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IVOB | 13,200,183 | — |
Shares reported on the most recent Form 4, priced at the 2018-11-02 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IVOB | SELL | 2017-02-15 | 2017-07-03 | $0.15 | $60K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.